Imugene - Crunchbase Company Profile & Funding

Q: Where is Imugene's headquarters?

Imugene is located in Sydney, New South Wales, Australia.

Q: Who invested in Imugene?

Imugene is funded by Precision BioSciences.

Q: When was the last funding round for Imugene?

Imugene closed its last funding round on obfuscated from a Post-IPO Equity round.

Overview

Imugene

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Imugene

CB Rank

109416

Imugene is a publicly-listed biotechnology company with operations in America and Europe,

Founded

obfuscation

Public

Post-IPO Equity

Sydney, New South Wales, Australia

51-100

www.imugene.com/

Biotechnology

Health Care

Funding Rounds

Post-IPO Equity

OBF

obfuscation

Post-IPO Equity

OBF

obfuscation

Post-IPO Debt

OBF

obfuscation

Key People

Paul Hopper: Executive Director
Past Role: Polynoma, Founder
Leslie Chong: CEO
Past Role: Genentech, Sr. Clinical Program Leader

Details

Legal Name

Imugene Limited

Operating Status

Active

Stock Symbol

ASX:IMU

Company Type

For Profit

Founders

Paul Hopper

About the Company

Imugene is a clinical-stage immuno-oncology firm researching a variety of innovative medicines that aim to engage cancer patients' immune systems in order to find and eradicate tumors. OnCARlytics (CF33-CD19) is a novel and successful combination immunotherapy that uses the CF33 oncolytic virus to deliver and show CD19 antigen on the surface

of cancer cells, enabling CD19 CAR T cell anti-tumor responses against solid tumors.

Predictions & Insights

Growth Insight

See this Growth Insight

Imugene is

Lorem

to be growing

Top Contributing Factors

Recently Raised Funding

Products & Services

Azer-cel

An off-the-shelf allogeneic CAR T cell therapy targeting CD19 to treat blood cancer.

onCARlytics (CF33-CD19)

A combination immunotherapy using the CF33 oncolytic virus to target solid tumors by expressing CD19 antigen on cancer cells.

Research & Development

Imugene is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Equity - Imugene	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Imugene	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Imugene	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Imugene	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Imugene	—	obfuscated obfuscation	—	Post-IPO Equity

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Equity - Imugene	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Imugene	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Imugene	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Imugene	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Imugene	—	obfuscated obfuscation	—	Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Precision BioSciences	Yes	Post-IPO Equity - Imugene	—
Precision BioSciences	Yes	Post-IPO Equity - Imugene	—
Precision BioSciences	Yes	Post-IPO Equity - Imugene	—
Precision BioSciences	Yes	Post-IPO Equity - Imugene	—
Precision BioSciences	Yes	Post-IPO Equity - Imugene	—